189 related articles for article (PubMed ID: 23800975)
1. Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR.
Villella VR; Esposito S; Maiuri MC; Raia V; Kroemer G; Maiuri L
Autophagy; 2013 Sep; 9(9):1431-4. PubMed ID: 23800975
[TBL] [Abstract][Full Text] [Related]
2. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator.
Luciani A; Villella VR; Esposito S; Gavina M; Russo I; Silano M; Guido S; Pettoello-Mantovani M; Carnuccio R; Scholte B; De Matteis A; Maiuri MC; Raia V; Luini A; Kroemer G; Maiuri L
Autophagy; 2012 Nov; 8(11):1657-72. PubMed ID: 22874563
[TBL] [Abstract][Full Text] [Related]
3. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.
De Stefano D; Villella VR; Esposito S; Tosco A; Sepe A; De Gregorio F; Salvadori L; Grassia R; Leone CA; De Rosa G; Maiuri MC; Pettoello-Mantovani M; Guido S; Bossi A; Zolin A; Venerando A; Pinna LA; Mehta A; Bona G; Kroemer G; Maiuri L; Raia V
Autophagy; 2014; 10(11):2053-74. PubMed ID: 25350163
[TBL] [Abstract][Full Text] [Related]
4. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition.
Luciani A; Villella VR; Esposito S; Brunetti-Pierri N; Medina D; Settembre C; Gavina M; Pulze L; Giardino I; Pettoello-Mantovani M; D'Apolito M; Guido S; Masliah E; Spencer B; Quaratino S; Raia V; Ballabio A; Maiuri L
Nat Cell Biol; 2010 Sep; 12(9):863-75. PubMed ID: 20711182
[TBL] [Abstract][Full Text] [Related]
5. Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator.
Villella VR; Esposito S; Bruscia EM; Vicinanza M; Cenci S; Guido S; Pettoello-Mantovani M; Carnuccio R; De Matteis MA; Luini A; Maiuri MC; Raia V; Kroemer G; Maiuri L
Cell Death Differ; 2013 Aug; 20(8):1101-15. PubMed ID: 23686137
[TBL] [Abstract][Full Text] [Related]
6. Novel cystamine-core dendrimer-formulation rescues ΔF508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy.
Faraj J; Bodas M; Pehote G; Swanson D; Sharma A; Vij N
Expert Opin Drug Deliv; 2019 Feb; 16(2):177-186. PubMed ID: 30732491
[TBL] [Abstract][Full Text] [Related]
7. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of autophagy inducers in epithelial cells carrying the ΔF508 mutation of the cystic fibrosis transmembrane conductance regulator CFTR.
Zhang S; Stoll G; Pedro JMBS; Sica V; Sauvat A; Obrist F; Kepp O; Li Y; Maiuri L; Zamzami N; Kroemer G
Cell Death Dis; 2018 Feb; 9(2):191. PubMed ID: 29415993
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect.
Villella VR; Esposito S; Bruscia EM; Maiuri MC; Raia V; Kroemer G; Maiuri L
Front Pharmacol; 2013; 4():1. PubMed ID: 23346057
[TBL] [Abstract][Full Text] [Related]
10. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
12. Can correcting the ΔF508-CFTR proteostasis-defect rescue CF lung disease?
Valle CW; Vij N
Curr Mol Med; 2012 Aug; 12(7):860-71. PubMed ID: 22697346
[TBL] [Abstract][Full Text] [Related]
13. New horizons in the treatment of cystic fibrosis.
Cuthbert AW
Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631
[TBL] [Abstract][Full Text] [Related]
14. The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells.
Swiatecka-Urban A; Brown A; Moreau-Marquis S; Renuka J; Coutermarsh B; Barnaby R; Karlson KH; Flotte TR; Fukuda M; Langford GM; Stanton BA
J Biol Chem; 2005 Nov; 280(44):36762-72. PubMed ID: 16131493
[TBL] [Abstract][Full Text] [Related]
15. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
16. Regulation of cystic fibrosis transmembrane conductance regulator by microRNA-145, -223, and -494 is altered in ΔF508 cystic fibrosis airway epithelium.
Oglesby IK; Chotirmall SH; McElvaney NG; Greene CM
J Immunol; 2013 Apr; 190(7):3354-62. PubMed ID: 23436935
[TBL] [Abstract][Full Text] [Related]
17. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
18. Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation.
Ferrari E; Monzani R; Villella VR; Esposito S; Saluzzo F; Rossin F; D'Eletto M; Tosco A; De Gregorio F; Izzo V; Maiuri MC; Kroemer G; Raia V; Maiuri L
Cell Death Dis; 2017 Jan; 8(1):e2544. PubMed ID: 28079883
[TBL] [Abstract][Full Text] [Related]
19. Depletion of the ubiquitin-binding adaptor molecule SQSTM1/p62 from macrophages harboring cftr ΔF508 mutation improves the delivery of Burkholderia cenocepacia to the autophagic machinery.
Abdulrahman BA; Khweek AA; Akhter A; Caution K; Tazi M; Hassan H; Zhang Y; Rowland PD; Malhotra S; Aeffner F; Davis IC; Valvano MA; Amer AO
J Biol Chem; 2013 Jan; 288(3):2049-58. PubMed ID: 23148214
[TBL] [Abstract][Full Text] [Related]
20. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.
Tosco A; De Gregorio F; Esposito S; De Stefano D; Sana I; Ferrari E; Sepe A; Salvadori L; Buonpensiero P; Di Pasqua A; Grassia R; Leone CA; Guido S; De Rosa G; Lusa S; Bona G; Stoll G; Maiuri MC; Mehta A; Kroemer G; Maiuri L; Raia V
Cell Death Differ; 2016 Aug; 23(8):1380-93. PubMed ID: 27035618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
